Multiomics Market Size, Share and Trends 2026 to 2035

What is the Multiomics Market Size?

The global multiomics market size is calculated at USD 3.24 billion in 2025 and is predicted to increase from USD 3.70 billion in 2026 to approximately USD 13.20 billion by 2035, expanding at a CAGR of 15.18% from 2026 to 2035.

Multiomics Market Key Takeaways

• In terms of revenue, the global multiomics market was valued at USD 3.24 billion in 2025.
• It is projected to reach USD 13.20 billion by 2035.
• The market is expected to grow at a CAGR of 15.18% from 2026 to 2035
• North America accounted for the largest revenue share of 45.73% in 2025.
• Asia Pacific is expected to grow at a significant CAGR of 18.35% from 2026 to 2035.
• By offering/component, the products segment dominated the market with the largest share of 79% in 2025.
• By offering/component, the services segment is expected to grow at the fastest CAGR of 15.80% between 2026 and 2035.
• By platform, the genomics segment held the largest market share of 39.47% in 2025.
• By platform, the proteomics segment is expected to expand at the fastest CAGR of 15.86% in the upcoming period.
• By application, the oncology segment dominated the market in 2025, accounting for the largest share of 39%.
• By application, the neurology segment is expected to expand at the fastest CAGR of 15.92% over the forecast period.
• By end user, the academic & research institutes segment led the market, holding a major share of 47% in 2025.
• By end user, the pharmaceutical & biotechnology companies segment is expected to grow at the fastest CAGR of 17.15% in the coming years.
• By type, the bulk multiomics segment held the dominant market share of 62% in 2025.
• By type, the single-cell multiomics segment is expected to grow at the fastest CAGR of 18.15% over the projection period.
• By technology, the next-generation sequencing (NGS) segment dominated the market with largest share of 49% in 2025 and is expected to sustain its dominance throughout the
• forecast period.

Market Overview

The multiomics market encompasses the integrated analysis of data across multiple omics domains, including genomics, proteomics, transcriptomics, metabolomics, and epigenomics, to gain a comprehensive, system-level understanding of biological processes. This approach is driving significant growth due to its potential to revolutionize personalized medicine, biomarker discovery, drug development, and clinical diagnostics by combining diverse molecular data types to uncover disease mechanisms, patient responses, and therapeutic targets. The rising prevalence of various life-threatening diseases, high demand for precision medicine, and advances in next-generation sequencing technologies are boosting the growth of this market.

How is AI Transforming the Multiomics Market?

Artificial intelligence is transforming the multiomics market by enabling faster and more efficient analysis of large datasets from various omics fields, leading to breakthroughs in understanding diseases, drug discovery, and personalized medicine. AI algorithms can integrate and analyze data from genomics, proteomics, metabolomics, and other sources to identify disease subtypes, drug targets, and biomarkers. AI also accelerates drug discovery by identifying potential drug targets, predicting efficacy, and optimizing drug design, contributing to improved diagnoses and prognoses. It can develop predictive models to identify individuals at risk for certain diseases or predict their treatment responses.

• In October 2024, at the ESGCT Congress, Whitelab Genomics shared key insights on how AI can transform genomic medicine. Their platform uses extensive datasets to create in-silico simulations that streamline the design and optimization of AAV vectors, drastically reducing development timelines while improving targeting specificity, aiming to unlock the full potential of genomic medicine.
  (Source: https://whitelabgx.com)

What Are the Key Trends in the Multiomics Market?

• Increasing Prevalence of Chronic Diseases: The rising prevalence of chronic diseases, including cancer, diabetes, and cardiovascular diseases, is driving the demand for multiomics approaches to understand disease mechanisms and identify new therapeutic targets, leading to more effective diagnostic and therapeutic strategies.
• Growing Demand for Single-Cell Multiomics: The emergence of single-cell multiomics is enabling researchers to study cellular heterogeneity and dynamics at an unprecedented level, gaining traction, and leading to discoveries in disease and treatment response, thereby further expanding the market.
• Increased Research and Development Investments: Investments in multiomics research and development by pharmaceutical and biotechnology companies are accelerating the development and adoption of multiomics technologies for the translation of multiomics research into clinical applications.
• Advancements in Technologies: Advances in high-throughput technologies, such as next-generation sequencing (NGS) and mass spectrometry, combined with advanced data analysis tools and bioinformatics, are enabling more efficient and comprehensive multiomics analysis, significantly improving the ability to generate vast amounts of omics data and driving the growth of multiomics.

Market Scope

Market Dynamics

Drivers

Increasing Drug Discovery and Development

The major driver in the multiomics market is the increasing drug discovery and development. Multiomics offers a more comprehensive understanding of disease mechanisms, enabling more targeted therapeutic approaches. Multiomics combines data from various omics fields to offer a holistic view of disease at the molecular level, which helps identify new drug targets and pathways involved in disease development. Therefore, by analyzing an individual's multi-omics profile, researchers can identify biomarkers that predict drug response, leading to the development of personalized therapies tailored to specific patient characteristics. It can also uncover new indications for existing drugs and speed up their repurposing for new therapeutic areas.

• In January 2025, Enhanc3D Genomics announced the launch of a suite of integrated multi-omics solutions designed to accelerate and improve the precision of drug discovery. Built on the Company's proprietary 3D genomics platform and integrated with extensive multi-omics analysis, the new 3D Multi-omics offerings provide partners with a comprehensive end-to-end solution to support and enhance decision-making throughout every stage of the drug discovery and development process.
  (Source: https://enhanc3dgenomics.com)

Restraint

High Cost and Complexity of Data Analysis and Integration

The primary restraint in the multiomics market is the high cost and complexity of data analysis and integration. This includes the need for specialized equipment and advanced bioinformatics software across genomics, proteomics, transcriptomics, and metabolomics, as well as highly skilled personnel with expertise in bioinformatics, data analysis, and interpretation. This makes adoption expensive for many institutions and companies. Different omics datasets have varying formats and structures, making integration and analysis challenging. Developing and implementing robust bioinformatics pipelines for multiomics analysis is complex and time-consuming.

Opportunity

Rising Demand for Personalized Medicine and Precision Diagnostics

The key future opportunity in the multiomics market lies in the rising demand for personalized medicine and precision diagnostics. Multiomics helps customize medical treatments based on individual patient profiles by integrating data from genomics, transcriptomics, proteomics, and metabolomics to gain a deeper understanding of disease mechanisms. This leads to more effective, personalized healthcare. Multiomics can help identify new drug targets and predict treatment responses, facilitating the development of more targeted therapies. Researchers can also discover novel biomarkers for early disease detection and prognosis by analyzing multiple omics layers.

Segment Analysis

Offering Insights

The Products Segment Dominate the Market in 2025

The products segment dominated the market in 2025 with the largest share, driven primarily by the high demand for high-throughput instruments, specialized consumables, and integrated software. Multiomics studies require multiple layers of sample processing, assay panels, and reagents, resulting in a recurring, high-volume market. Continuous innovation in high-throughput instruments enhances detection capabilities and accelerates data generation. Additionally, software for data integration is a rapidly growing sub-segment of products, essential for managing the complex datasets produced by multiomics studies.

The services segment is expected to grow at the fastest CAGR during the forecast period. This growth is largely due to the complexities of data, a shortage of specialized bioinformatics expertise, and the need for cost-effective, end-to-end solutions. The vast and heterogeneous datasets generated by multiomics require specialized bioinformatics and data integration skills that many academic institutions and smaller pharmaceutical companies lack in-house. Outsourcing these services allows these institutions to access advanced technologies without the substantial upfront capital costs associated with purchasing high-end instruments.

Multiomics Market Size, By Offering, 2023 to 2025 (USD Million)

Platform Insights

Why Did the Genomics Segment Lead the Market in 2025?

The genomics segment led the multiomics market in 2025, primarily because of its foundational role in Next-Generation Sequencing (NGS). This dominance is supported by declining sequencing costs, high-throughput technologies, and widespread adoption in oncology, personalized medicine, and government-funded genomic research projects. Enhancements in high-throughput NGS platforms and long-read sequencing have significantly improved speed, accuracy, and accessibility. Since genomics serves as the foundation for multiomics analysis, including integrating proteomics and metabolomics, it is indispensable in both research and clinical settings.

The proteomics segment is anticipated to grow the fastest CAGR during the forecast period, largely due to advancements in high-throughput mass spectrometry and next-generation sequencing, as well as an increasing demand for biomarker discovery. As researchers and companies outsource complex data analysis, protein identification, and characterization to specialized firms, the investments made by pharmaceutical companies in understanding protein structure and function for drug discovery, along with the growing adoption of precision medicine, serve as primary growth catalysts.

Multiomics Market Size, By Platform, 2023 to 2025 (USD Million)

Application Insights

The Oncology Segment Held the Largest Market Share in 2025

The oncology segment dominated the multiomics market with the largest share in 2025, primarily due to the rising demand for precision medicine, early cancer detection, and a deeper understanding of complex tumor heterogeneity. Multiomics enables researchers to analyze various tumor subtypes and study individual cancer cells to understand treatment resistance and relapse. By integrating multiple datasets, companies can identify novel biomarkers related to disease progression, leading to more effective and personalized treatment plans. Major industry players are focusing on advancements in spatial proteomics and single-cell multiomics tailored for oncology applications.

The neurology segment is projected to grow at the fastest CAGR during the forecast period, primarily due to the urgent need to understand complex neurodegenerative diseases like Alzheimer's and Parkinson's, which affect over one-third of the global population. Neurological disorders are highly heterogeneous, making multiomics essential for studying the interactions between genes, proteins, and metabolites to identify new biomarkers. Technologies such as spatial proteomics and single-cell multiomics allow researchers to map molecular changes surrounding pathological plaques in Alzheimer's disease with unprecedented resolution, enabling earlier detection and improved patient stratification.

Multiomics Market Share, By Application, 2025 (%)

End User Insights

How do Academies & Research Institutes Lead the Market in 2025?

In 2025, the academic & research institutes segment led the multiomics market with the largest share. This is mainly due to their surging investments in multiomics to design precision, patient-specific therapies, especially for complex diseases, such as cancer and neurological disorders. Moreover, these institutes are spurring alliances with biotech & pharma companies to develop innovative technologies, de-risk research pipelines, & foster drug discovery.

The pharmaceutical & biotechnology companies segment is expected to grow at the fastest CAGR in the coming years. This is mainly due to the growing pipeline of targeted therapies and tailored treatment, specifically in oncology. Increasing focus of these companies in R&D for drug discovery and development, along with the need to streamline processes and improve drug candidate properties, also drives segmental growth. Moreover, these companies often partner with Contract Research Organizations that have specialized multiomics expertise, allowing them to leverage external capabilities without heavy investments in infrastructure and talent.

Multiomics Market Size, By End User, 2023 to 2025 (USD Million)

Type Insights

The Bulk Multiomics Segment Held a Major Share of the Market in 2025

The bulk multiomics segment registered dominance in the market in 2025 by holding the largest share. This is mainly due to its streamlined workflows & reduced spending per sample, which makes it suitable for large-scale studies. This type is widely incorporated in more straightforward, mature protocols, accelerating research in drug discovery & validation.

The single-cell multiomics segment is projected to expand at the fastest rate over the forecast period. The growth of the segment is driven by ongoing groundbreakings in single-cell isolation, barcoding technologies, and the integration of AI-powered, cloud-based software for data analysis. Single-cell multiomics play a pivotal role in demonstrating cellular heterogeneity, distinguishing various cell types & dynamic states within a sample. This makes it the preferred choice, especially in research activities.

Multiomics Market Size, By Type, 2023 to 2025 (USD Million)

Technology Insights

The NGS Segment Leads the Multiomics Market

In 2025, the next-generation sequencing (NGS) segment dominated the market with the largest share and is expected to grow at the fastest CAGR in the coming years. This is mainly due to its lower expenditure, along with high throughput. Also, it has a major role in customized treatment and robust clinical diagnostics. This technology enables researchers to opt between deep sequencing for specific, targeted regions or broad, shallow sequencing for whole-genome, metagenomic, or transcriptomic profiling. The segment's growth is also driven by ongoing advances in sequencing technologies.

Multiomics Market Share, By Technology, 2025 (%)

U.S. Multiomics Market Size and Growth 2026 to 2035

The U.S. multiomics market size was exhibited at USD 1.19 billion in 2025 and is projected to be worth around USD 4.01 billion by 2035, growing at a CAGR of 13.02% from 2026 to 2035.

What Made North America the Dominant Region in the Multiomics Market in 2025?

North America dominated the global market with a 45.73% share in 2025. This is primarily due to its robust research infrastructure and substantial investments in healthcare and biotech R&D, which are supported by both government and private sector funding. The region benefits from the presence of major life science companies, including Thermo Fisher Scientific, Illumina, Agilent Technologies, and QIAGEN, which leads to innovations in the multiomics approach. North America also boasts world-class research institutions, including Harvard, MIT, and the NIH, which lead to increased research activities. Government programs, NIH's multiomics investments, and the FDA's support for biomarker-guided drug development provide essential financial and regulatory backing.

U.S. Multiomics Market Trends

The U.S. is leading the charge. The market within the U.S. is driven by strong research infrastructure, significant government funding, and the presence of prominent biotechnology and pharmaceutical companies. The country is at the forefront of developing and applying advanced technologies like next-generation sequencing, mass spectrometry, and bioinformatics tools for multiomics analysis. Additionally, the U.S. market is marked by intense competition, active research and development efforts, and a focus on personalized medicine, further boosting the multiomics sector.

What Factors Support Asia Pacific's Growth in the Multiomics Market?

Asia Pacific is expected to grow at the fastest CAGR of 18.35% from 2026 to 2035, owing to increasing investments in life sciences research, a rising number of biotech startups, and expanding healthcare infrastructure, especially in countries like China, Japan, and India. Governments across the region actively encourage biotech growth through various initiatives and policies, such as India's National Development Programmes (NDPs) and Sustainable Development Goals (SDGs), which support biotech development and promote biomanufacturing. With the growing prevalence of various diseases, there is a strong focus on novel drug discovery, contributing to regional market growth.

China Multiomics Market Trends

China is a major player in the market within Asia Pacific. This is mainly due to its substantial investments in genomics research, precision medicine initiatives, and biotech development. China is emerging as a leader in multiomics. There is a widespread application of multiomics in areas such as disease diagnosis and treatment. Companies like BGI Group are key players in China's multiomics landscape.

India Multiomics Market Trends

India also plays a significant role in the market, fueled by increasing emphasis on personalized medicine, advances in high-throughput technologies, and government investments in life science R&D. The multiomics approach is vital for understanding complex diseases and developing targeted therapies. India's contribution is especially notable in cancer research, with initiatives like the Indian Cancer Genome Atlas (ICGA) creating valuable datasets for personalized treatment.

Why Does Europe Consider a Significant Region in the Multiomics Market?

Europe is considered to be a significantly growing area. This is primarily due to its greater emphasis on genomics research, substantial government funding, and the increasing adoption of personalized healthcare. European governments support multiomics through initiatives like the France Genomic Medicine Plan 2025 and research programs such as Horizon Europe. Projects like the 1+ Million Genomes and collaborations like EATRIS-Plus demonstrate Europe's commitment to advancing multiomics research and integrating it into healthcare.

How Will Latin America Make an Impact on the Multiomics Market?

Latin America is experiencing steady growth in the market, driven by its diverse population, increasing focus on personalized medicine, and expanding healthcare infrastructure. While not specific to multiomics, broader advancements in technology and healthcare, along with government support for innovation, create a fertile environment for the adoption of multiomics. Brazil actively promotes biotech research, including investments in genomics and related fields, which support multiomics applications. Favorable trade agreements and rising foreign investment further boost the region's economic growth, making it more attractive for multiomics companies.

What Opportunities Exist in the Middle East and Africa Multiomics Market?

The Middle East and Africa are also witnessing notable growth in the multiomics sector, driven by increased investments in healthcare infrastructure, heightened awareness of precision medicine, and collaborations between local and global entities. Several government initiatives and partnerships focus on healthcare advancement and biotech development. The UAE emphasizes healthcare improvements, boosting the adoption of multiomics technologies. Companies such as BD, Thermo Fisher Scientific, Illumina, and QIAGEN are expanding their presence in the region, thereby supporting market growth.

What are the Advancements in Europe?

Europe is witnessing significant amount of growth in the multiomics market. This growth is because the region benefits from strong governmental support for research initiatives and also has a growing emphasis on personalized medicine. Regulatory frameworks, such as the European Medicines Agency guidelines, are encouraging the adoption of multiomics technologies, bringing awareness and driving demand across various sectors, including pharmaceuticals and diagnostics. The region also has a strong presence of various research institutions, with collaborations between academia and industry fostering innovation. Leading countries in this region include Germany, the UK and France.

What are the Advancements in Latin America?

The Latin American market is witnessing substantial growth in the recent years and is expected to keep growing steadily in the forecast years as well. This growth is driven by the increasing need for comprehensive biological analysis, rising technological advancements in sequencing and proteomics, and expanding clinical applications especially in the field of precision medicine. With rising investments in healthcare and data integration platforms, the region is positioned to accelerate in the multiomics adoption.

What are the Advancements in The Middle East and Africa?

The Middle East and Africa region is gradually emerging in the market and is expected to maintain its growth rate. This is due to the increasing amounts of investments that are being made in healthcare infrastructure, the rising awareness of personalized medicine, and strong government initiatives which are aimed at enhancing research capabilities. Countries like South Africa and the UAE are leading in the region, as they are focused on developing advanced healthcare solutions and fostering innovation. The presence of key players is quite limited, but collaborations with global firms are gaining traction, thus enhancing the region's position in the global market.

Value Chain Analysis

• Raw Material and Data Sourcing
  The foundation of multiomics begins with the collection of biological samples such as tissues, blood and cells. Quality is of great priority in this stage as it helps to determine data reliability. In the recent years, the demand for high throughput, high volume reagent kits and consumables has surged, making scalability and consistency a priority for suppliers. This growth is driven by large pharmas and research.
  Key Players: Agilent, Thermo Fisher, Bio Rad
• Manufacturing Process
  This stage involves building the core of any multiomics platform. Manufacturers all over the world are expanding the production of high throughput instruments and consumables in order to meet the growing demand. Because multiomics data generation creates massive amounts of data sets, companies are also seen investing in computational infrastructure like servers, cloud based platforms and advanced data storage softwares.
  Key Players: Illumina, Perkin Elmer, Bruker Corporation
• Product Innovation and Designing
  This stage focuses on improving instruments as well as refining workflows by combing various omics layers in order to deliver holistic biological insights, thus enabling precision medicine, biomarker discovery and systems biology research. A major trend in this stage is the rise of single cell multiomics, which allows researchers to analyze cellular nuances and disease mechanisms on a much deeper level.
  Key Players: Thermo Fisher, BGP Genomics, QIAGEN

Multiomics Market Companies

• Thermo Fisher Scientific
• Illumina, Inc.
• Agilent Technologies
• QIAGEN
• Bruker Corporation
• BGI Genomics
• PerkinElmer (now part of Revvity)
• Waters Corporation
• Bio-Rad Laboratories
• 10x Genomics

Latest Announcement by Industry Leader

• In January 2025, Illumina, Inc. collaborated with NVIDIA to advance technology platforms for the analysis and interpretation of multiomic data, accelerating progress in clinical research, genomics AI development, and drug discovery. Rory Kelleher, senior director, global head of business development, healthcare and life sciences at NVIDIA, said, "Combining Illumina's world-leading sequencing and analytics platforms with NVIDIA's accelerated computing and AI, we will drive the next generation of genomics interpretation and democratize genomics for drug discovery through AI-powered insights."
  (Source: https://pharmabiz.com)

Segments Covered in the Report

By Products

• Instruments
• Consumables
• Software
• Services

By Platform

• Genomics
• Transcriptomics
• Proteomics
• Metabolomics

By Application

• Oncology
• Neurology
• Immunology
• Cell Biology

By End User

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Others

By Type

• Single-cell Multiomics
• Bulk Multiomics

By Technology

• Next-Generation Sequencing (NGS)
• Mass Spectrometry (MS)
• PCR & Microarrays

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa